Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Fibromyalgia Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Fibromyalgia Overview | 9 | 1 |
| Pipeline Products for Fibromyalgia Comparative Analysis | 10 | 1 |
| Fibromyalgia Therapeutics under Development by Companies | 11 | 1 |
| Fibromyalgia Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Fibromyalgia Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Fibromyalgia Products under Development by Companies | 16 | 1 |
| Fibromyalgia Products under Investigation by Universities/Institutes | 17 | 1 |
| Fibromyalgia Companies Involved in Therapeutics Development | 18 | 7 |
| Astellas Pharma Inc. | 18 | 1 |
| Daiichi Sankyo Company, Limited | 19 | 1 |
| Merck &Co., Inc. | 20 | 1 |
| SWITCH Biotech LLC | 21 | 1 |
| Theravance Biopharma, Inc. | 22 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 23 | 1 |
| Zynerba Pharmaceuticals, Inc. | 24 | 1 |
| Fibromyalgia Therapeutics Assessment | 25 | 10 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Combination Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 28 |
| (celecoxib + famciclovir) Drug Profile | 35 | 1 |
| AS-1069562 Drug Profile | 36 | 1 |
| ASP-0819 Drug Profile | 37 | 1 |
| ASP-8062 Drug Profile | 38 | 1 |
| AXIBU-04 Drug Profile | 39 | 1 |
| mirogabalin besylate Drug Profile | 40 | 2 |
| mirtazapine ODT Drug Profile | 42 | 1 |
| naltrexone hydrochloride Drug Profile | 43 | 3 |
| Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain Drug Profile | 46 | 1 |
| Small Molecules for Fibromyalgia Drug Profile | 47 | 1 |
| SWT-06101 Drug Profile | 48 | 1 |
| TD-9855 Drug Profile | 49 | 2 |
| TNX-102 Drug Profile | 51 | 8 |
| U-2902 Drug Profile | 59 | 2 |
| ZYN-001 Drug Profile | 61 | 2 |
| Fibromyalgia Dormant Projects | 63 | 3 |
| Fibromyalgia Discontinued Products | 66 | 1 |
| Fibromyalgia Product Development Milestones | 67 | 12 |
| Featured News &Press Releases | 67 | 1 |
| Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia | 67 | 1 |
| Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention | 68 | 1 |
| May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia | 68 | 1 |
| Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting | 69 | 1 |
| Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia | 69 | 1 |
| Nov 10, 2015: Tonix Pharmaceuticals Presents Additional Data on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting | 70 | 1 |
| Oct 01, 2015: Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting | 71 | 1 |
| Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg | 72 | 1 |
| Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR | 72 | 2 |
| May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR | 74 | 1 |
| May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR | 75 | 1 |
| May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia | 75 | 1 |
| Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin | 76 | 1 |
| Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia | 77 | 1 |
| Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study | 77 | 2 |
| Appendix | 79 | 2 |
| Methodology | 79 | 1 |
| Coverage | 79 | 1 |
| Secondary Research | 79 | 1 |
| Primary Research | 79 | 1 |
| Expert Panel Validation | 79 | 1 |
| Contact Us | 79 | 1 |
| Disclaimer | 80 | 1 |